Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: A detailed kinetic study and analysis of metabolites

Biochemical Pharmacology

Volumn 56, Issue 5, 1998, Pages 613-621

  Bailey, Susan M ^a   Lewis, Alex D ^a   Knox, Richard J ^b   Patterson, Laurence H ^c   Fisher, Geoff R ^c   Workman, Paul ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c School of Applied Sciences   (United Kingdom)

Author keywords

Bioreductive agents; Electron spin resonance spectroscopy; EO9; Hypoxia; Reduction

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; NEW DRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; ELECTRON SPIN RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; WALKER CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA 256, WALKER; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME C GROUP; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; HT29 CELLS; HUMANS; INDOLEQUINONES; INDOLES; KINETICS; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; RATS; TUMOR CELLS, CULTURED;

EID: 0032168217     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00661-8     Document Type: Article

References (45)

1. Oostveen E.A., Speckamp W.N. Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron. 43:1987;255-262.
2. Hendriks H.R., Pizao P.E., Berger D.P., Kooistra K.L., Bibby M.C., Boven E., Dreef-van der Meulen HC. EO9 A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models . Eur J Cancer. 29A:1993;897-906.
3. Lewis A.D., Clarke P.W., Deng P.S.K., Chen S., Workman P. Comparison of human and rodent recombinant DT-diaphorase proteins for their ability to metabolize the novel indoloquinone antitumour agent EO9. Proc Am Assoc Cancer Res. 35:1994;384.
4. Schellens J.H., Planting A.S., van-Acker B.A., Loos W.J., de-Boer-Dennert M., van-der-Burg M.E., Koier I. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst. 86:1994;906-912.
5. Wanders J., Pavlidis N., Gamucci T., Huinink W.W.T., Dirix L., Wolff I., Verweij J. Phase-II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC. Eur J Cancer. 31A:1995;565-565.
6. Pavlidis N., Hanauske A.R., Gamucci T., Smyth J., Lehnert M., Tevelde A., Lan J. A randomized phase-II study with 2 schedules of the novel indoloquinone-EO9 in non-small-cell lung-cancer - a study of the EORTC early clinical-studies group (ECSG). Annals Oncol. 7:1996;529-531.
7. Bachur N.R., Gordon S.L., Gee M.V., Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA. 76:1979;954-957.
8. Fisher G.R., Gutierrez P.L. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase. Free Radical Biol Med. 11:1991;597-604.
9. Keyes S.R., Fracasso P.M., Heimbrook D.C., Rockwell S., Sligar S.G., Sartorelli A.C. Role of NADPH: cytochrome c reductase and DT-diaphroase in the biotransformation of mitomycin C. Cancer Res. 44:1984;5638-5643.
10. 5 reductase. Cancer Lett. 84:1994;149-154.
11. Riley R.J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 43:1992;1657-1669.
12. Workman P. Design of novel bioreductive drugs. Workman P. New approaches in cancer pharmacology: drug design and development. 1992;63-74 Springer-Verlag, Berlin.
13. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 50:1990;7293-7300.
14. Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., Roberts J.J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-hydroxylamino-2-nitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2,4-dinitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol. 37:1988;4671-4677.
15. Bailey S.M., Suggett N., Walton M.I., Workman P. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys. 22:1992;649-653.
16. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 50:1990;7483-7489.
17. Schor N.A., Cornelisse C.J. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res. 43:1983;4850-4855.
18. Schlager J.J., Powis G. Cytosolic NAD(P)H, (quinone-acceptor) oxidoreductase in human normal and tumour tissue: Effects of cigarette smoking and alcohol. Int J Cancer. 45:1990;403-409.
19. 1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol. 42:1991;1021-1027.
20. Malkinson A.M., Siegel D., Forrest G.L., Gazdar A.F., Oie H.K., Chan D.C., Bunn P.A. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res. 52:1992;4752-4757.
21. Walton M.I., Smith P.J., Workman P. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive activation of the novel indoloquinone antitumour agent EO9. Cancer Commun. 3:1991;199-206.
22. Walton M.I., Suggett N., Workman P. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys. 22:1992;643-648.
23. Boland M.P., Knox R.J., Roberts J.J. The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol. 41:1991;867-875.
24. Gustafson D.L., Pritsos C.A. Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol. Cancer Res. 52:1992;6936-6939.
25. Workman P., Walton M.I. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer. 60:1989;800-802.
26. Knox R.J., Friedlos F., Jarman M., Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridni-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker Carcinoma cells. Biochem Pharmacol. 37:1988;4661-4669.
27. Ernster L., Danielson L., Ljunggren M. DT-diaphorase 1. Purification from the soluble fraction of rat-liver cytoplasm and properties. Biochim Biophys Acta. 58:1962;171-188.
28. Finkelstein E., Rosen G.M., Rauckman E.J., Paxton J. Spin trapping of superoxide. Mol Pharmacol. 16:1979;676-685.
29. Pou S., Hassett D.J., Britigan B.E., Cohen M.S., Rosen G.M. Problems associated with spin trapping oxygen-centered free radicals in biologic systems. Anal Biochem. 177:1989;1-6.
30. Workman P., Walton M.I. Enzyme-directed bioreductive drug development. Adams G.E., Breccia A., Fielden E.M., Wardman P. Selective activation of drugs by redox processes. 1990;173-191 Plenum Press, New York.
31. Workman P, Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. 6: 461-475, 1994.
32. Plumb J.A., Gerritsen M., Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer. 70:1994;1136-1143.
33. Robertson N., Haigh A., Adams G., Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer. 30A:1994;1013-1019.
34. Smitskamp-Wilms E., Peters G.J., Pinedo H.M., van Ark-Otte J., Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol. 47:1994;1325-1332.
35. Collard J., Matthew A.M., Double J.A., Bibby M.C. EO9 relationship between DT-diaphorase and response in vitro and in vivo . Br J Cancer. 1995:1995;1199-1203.
36. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., Lewis A.D. Reductase enzyme expression across the National Cancer Institute tumor-cell line panel - correlation with sensitivity to mitomycin-C and E09. J Natl Cancer Inst. 88:1996;259-269.
37. Coleman C.N. Hypoxia in tumours: a paradigm for the approach to biochemical and physiological heterogeneity. J Natl Cancer Inst. 80:1988;310-317.
38. Plumb J.A., Workman P. Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer. 56:1994;134-139.
39. Plumb J.A., Gerritsen M., Milroy R., Thomson P., Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 29:1994;295-299.
40. Maliepaard M., Wolfs A., Groot S.E., de Mol N.J., Janssen L.H.M. Indoloquinone EO9, DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer. 71:1995;836-839.
41. Patterson L.H., Jones S., Gesher A. A generation of a free radical from calphostin c by microsomal cytochrome P450 reductase in rat and human liver. Biochem Pharmacol. 51:1996;599-603.
42. Iyanagi T., Yamazaki I. I. One-electron transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochem Biophys Acta. 216:1970;282-294.
43. Butler J., Cummings J., Spanswick V.J. The autooxidation of reduced forms of EO9. Free Radical Res. 25:1996;141-146.
44. Bailey S.M., Lewis A.D., Patterson L.H., Fisher G.R., Workman P. Free radical generation following reduction of EO9: involvement in cytotoxicity. Br J Cancer. 67:1993;8.
45. Bailey S.M., Lewis A.D., Workman P. Involvement of NADPH:cytochrome P450 reductase in activation of EO9 to a DNA damaging species. Br J Cancer. 69:1994;57.